文献速递甲状腺疾病

接受抗甲状腺药物初始治疗的Graves病患者癌症风险:全国性人群分析

Cancer Risks of Patients with Graves' Disease Who Received Antithyroid Drugs as Initial Treatment: A Nationwide Population-Based Analysis.
PubMed 文献 · Thyroid · 2024-09-23

该全国性回顾性队列研究利用韩国国家健康信息数据库,纳入29,502例年龄>20岁、以抗甲状腺药物(ATD)初始治疗的Graves病(GD)患者及57,173例年龄性别匹配对照,评估各类癌症发病风险。GD组胆道癌与胰腺癌、甲状腺癌、前列腺癌、卵巢癌风险升高,且排除随访第一年及随访超过5年后仍持续;甲状腺癌风险在随访初期最高,可能为监测效应。

要点

  • GD患者胆道癌与胰腺癌、甲状腺癌、前列腺癌、卵巢癌风险升高
  • 排除随访第一年及随访超过5年后上述癌症风险仍持续
  • 甲状腺癌风险在随访1至<2年最高,可能为监测效应

核心结论

  • 在这项大型人群研究中,GD与胆道癌及胰腺癌、前列腺癌、卵巢癌、甲状腺癌风险升高相关。
  • 甲状腺癌风险升高尤其在随访初期出现,可能为监测效应。

研究设计与样本

  • 韩国国家健康信息数据库的全国性回顾性队列研究。
  • 纳入29,502例年龄>20岁、以ATD初始治疗的GD患者和57,173例年龄性别匹配对照。
  • 主要结局为各类癌症发病率,采用Cox比例风险模型估计风险比(HR)及置信区间(CI)。
  • 按GD诊断后随访时间分析HR以考虑监测效应。

主要发现

  • GD组较对照组胆道癌与胰腺癌风险升高(HR 1.41,CI 1.24-1.60),排除随访第一年后仍升高。
  • GD组较对照组甲状腺癌风险升高(HR 15.51,CI 12.29-19.57),排除随访第一年后仍升高。
  • GD组较对照组前列腺癌风险升高(HR 1.48,CI 1.28-1.71),排除随访第一年后仍升高。
  • GD组较对照组卵巢癌风险升高(HR 1.31,CI 1.13-1.52),排除随访第一年后仍升高。
  • 甲狀腺癌风险在随访1至<2年(HR 19.35,CI 7.66-48.87)高于随访超过2年。

关键数值与推荐

  • 胆道癌与胰腺癌:GD组HR 1.41(CI 1.24-1.60)。
  • 甲状腺癌:GD组HR 15.51(CI 12.29-19.57);随访1至<2年HR 19.35(CI 7.66-48.87)。
  • 前列腺癌:GD组HR 1.48(CI 1.28-1.71)。
  • 卵巢癌:GD组HR 1.31(CI 1.13-1.52)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Population-based studies that examine the associations between hyperthyroidism and cancer risk have yielded inconsistent results. It remains unclear whether the risks of different cancers increase in patients with Graves' disease (GD) who received antithyroid drugs (ATDs) as initial treatment. We aimed to determine whether cancer risk increases in patients with GD, compared with controls. Methods: This nationwide retrospective cohort study utilized data from the National Health Information Database of South Korea. We included 29,502 patients aged >20 years with GD, who received ATDs as initial treatment, and 57,173 age- and sex-matched controls. The primary outcome was the incidence of various types of cancers. Hazard ratios (HRs) with confidence intervals (CIs) for cancer risk were estimated using Cox proportional hazards models. We also analyzed HR by follow-up period since the diagnosis of GD, accounting for surveillance effect. Results: The risk of biliary tract and pancreatic cancers (HR: 1.41, CI: 1.24-1.60), thyroid cancer (HR: 15.51, CI: 12.29-19.57), prostate cancer (HR: 1.48, CI: 1.28-1.71), and ovarian cancer (HR: 1.31, CI: 1.13-1.52) was elevated in the GD group than in the control group even after the first year of follow-up was excluded. The increased risk of these cancers persisted after a follow-up period of more than 5 years. The risk of thyroid cancer in patients with GD was higher during the initial follow-up period (1 to <2 years) (HR: 19.35, CI: 7.66-48.87) compared with that in the follow-up period exceeding 2 years. The cancer risk estimates remained significant after excluding patients with GD who underwent subsequent radioactive iodine therapy. Conclusion: In this large-scale population-based study, GD was associated with increased risks of biliary tract and pancreatic, prostate, ovarian, and thyroid cancers. The increased risk of thyroid cancer, particularly during the initial follow-up period, may be a surveillance effect.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee JY, Lee MK, Lee JH, et al. Cancer Risks of Patients with Graves' Disease Who Received Antithyroid Drugs as Initial Treatment: A Nationwide Population-Based Analysis. Thyroid. 2024. PMID: 39228052. doi:10.1089/thy.2024.0178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。